Table 1.
Baseline characteristics of patients originating from three different Dutch hospitals (Erasmus Medical Center, Antoni van Leeuwenhoek Hospital, Sint Franciscus Gasthuis) who underwent POC and radical cystectomy for MIBC (N = 123). Patients are categorized by response to POC
| Variables | CR (n = 35) | PR (n = 11) | NR (n = 77) | P-value CR vs NR |
| Age, years (median, range) | 58 (45–77) | 57 (34–75) | 63 (35–76) | 0.76 |
| Gender | 0.82 | |||
| Male | 27 (77.1%) | 7 (63.6%) | 57 (74%) | |
| Female | 8 (22.9%) | 4 (36.4%) | 20 (26%) | |
| Smoking status | 0.74 | |||
| Never | 5 (14.3%) | – | 10 (13.0%) | |
| Former | 9 (25.7%) | 1 (9.1%) | 18 (23.4%) | |
| Current | 9 (25.7%) | 3 (27.3%) | 12 (15.6%) | |
| Unknown | 12 (34.4%) | 7 (63.6%) | 37 (48.1%) | |
| Charlson Comorbidity Index | 0.72 | |||
| 3 | 1 (2.9%) | 1 (9.1%) | – | |
| 4 | 4 (11.4%) | 2 (18.2%) | 7 (9.1%) | |
| 5 | 4 (11.4%) | – | 6 (7.8%) | |
| 6 | 2 (5.7%) | 2 (18.2%) | 4 (5.2%) | |
| 7 | – | – | 2 (2.6%) | |
| Unknown | 24 (68.6%) | 6 (54.5%) | 58 (75.3%) | |
| Karnofsky Performance Score | 0.20 | |||
| 70 | – | 1 (9.1%) | 1 (1.3%) | |
| 80 | – | – | 5 (6.5%) | |
| 90 | 8 (22.9%) | 2 (18.2%) | 8 (10.4%) | |
| 100 | 3 (8.6%) | 2 (18.2%) | 5 (6.5%) | |
| Unknown | 24 (68.6%) | 6 (54.5%) | 58 (75.3%) | |
| Tumor presentation | 0.30 | |||
| Primary | 23 (65.7%) | 10 (90.9%) | 58 (75.3%) | |
| Recurrence | 9 (25.7%) | 1 (9.1%) | 13 (16.9%) | |
| Unknown | 3 (8.6%) | – | 6 (7.8%) | |
| Clinical tumor stage | 0.11 | |||
| T1 | 3 (8.6%) | – | 1 (1.3%) | |
| T2 | 8 (22.9%) | 3 (27.3%) | 16 (20.8%) | |
| T3 | 17 (48.6%) | 6 (54.5%) | 31 (40.3%) | |
| T4 | 7 (20%) | 2 (18.2%) | 28 (36.4%) | |
| Unknown | – | – | 1 (1.3%) | |
| Extravesical extension at diagnostic imaging | 0.18 | |||
| Positive | 10 (28.6%) | 2 (18.2%) | 33 (42.9%) | |
| Negative | 17 (48.6%) | 7 (63.6%) | 29 (37.7%) | |
| Unknown | 8 (22.9%) | 2 (18.2%) | 15 (19.5%) | |
| Lymphadenopathy at diagnostic imaging | <0.01 | |||
| Positive | 8 (22.9%) | 4 (36.4%) | 40 (51.9%) | |
| Negative | 19 (54.3%) | 5 (45.5%) | 25 (32.5%) | |
| Unknown | 8 (22.9%) | 2 (18.2%) | 12 (15.6%) | |
| Hydronephrosis at diagnostic imaging | 0.17 | |||
| Positive | 9 (25.7%) | 5 (45.5%) | 32 (41.6%) | |
| Negative | 18 (51.4%) | 4 (36.4%) | 32 (41.6%) | |
| Unknown | 8 (22.9%) | 2 (18.2%) | 12 (16.9%) | |
| Hemoglobin level, mmol/L (median, range) | 8.3 (5.5–10.3) | 8.6 (7.3–9.5) | 8.0 (5.5–10.0) | 0.12 |
| Creatinine level, μmol/L (median, range) | 75 (56–209) | 76 (65–122) | 92 (46–186) | 0.28 |
| Glomerular Filtration Rate (GFR), ml/min (median, range) | 87 (35–115) | 80 (53–90) | 72 (44–124) | 0.56 |
| POC regimen | 0.51 | |||
| Cisplatin based | 26 (74.3%) | 10 (90.9%) | 51 (66.2%) | |
| Carboplatin based | 9 (25.7%) | 1 (9.1%) | 26 (33.8%) | |
| Recurrence after cystectomy | <0.01 | |||
| Yes | 7 (20%) | 2 (18.2%) | 48 (62.3%) | |
| No | 28 (80%) | 9 (81.8%) | 29 (37.7%) | |
| Last follow up status | <0.01 | |||
| Alive, no evidence of disease | 25 (71.4%) | 8 (72.7%) | 22 (28.6%) | |
| Alive, with recurrent disease | 3 (8.6%) | – | 6 (7.8%) | |
| Dead of non-disease | 3 (8.6%) | 1 (9.1%) | 5 (6.5%) | |
| Dead of disease | 3 (8.6%) | 2 (18.2%) | 39 (50.6%) | |
| Lost to follow up | 1 (2.9%) | – | 5 (6.5%) | |
| Time from dTUR to surgery, months (median, range) | 5.0 (3–8) | 5.0 (4–6) | 5.0 (2–19) | 0.30 |
| Time from POC to surgery, months (median, range) | 3.0 (2–4) | 3.0 (2–5) | 3.0 (1–9) | 0.67 |
CR, complete response; NR, non-response; PR, partial response; POC, pre-operative chemotherapy.